Conference abstract
Short communicationPublished 28 May 2021
The EU Pharmacovigilance System Master File (PSMF)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmacovigilance (PV) is the science relating to collecting, detecting, assessing, monitoring, and preventing adverse effects with pharmaceutical products. [1] The urgent need for this field within the pharmaceutical world became apparent after the two catastrophic events with sulphanilamide and thalidomide. Pharmacovigilance evolved drastically over the last few decades thanks to the experts creating legislations to properly control the safety, efficacy and quality of medicinal products. Despite that, new challenges are emerging. The year 2010 significantly shaped the currently known Pharma world introducing various updates to statutory and strengthening them. The newly introduced Directive 2010/84/EU amending Directive 2001/83/EC obliges each Market Authorisation Holder (MAH) with the EEA to have a socalled PSMF document in place for each Market Authorisation Application (MAA). The PSMF is a modular document describing the PV system which is utilised for the medicinal product by the MAH. It also supports the conduct of audits and inspections, confirms compliance of the PV system, highlights deficiencies in the system or non-compliance with the requirements, and highlights risks or actual failure in the conduct of specific aspects of PV. It is a key instrument and vital for a MAH, a dynamic document that also evolves with the MAH, and each section has to provide a detailed description of a specific aspect of the PV system. Due to its above-described nature, this document has to be provided to Competent Authorities upon request within seven days, if not otherwise specified. Although the information expected to be included within the PSMF is very well outlined in the legislation - GVP Module 2, findings identified during inspections suggest that some aspects of the legislation can be misunderstood.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 2018
An Overview of Drug Master Files
Conference abstract · 29 Sep 2016
Regulatory requirements and filing considerations for Type II master files
Conference abstract · 29 Sep 2016
Regulatory requirements and filling considerations for type II master files
Conference abstract · 8 Sep 2014
Active substance master files: What is changing in the EU regulatory framework for drug substances?
More from this journal
The newest in Journal of Pathobiology and Physiology.
Perspective · 28 Jun 2022
Profiling of microbes: Tools, techniques, and challenges
Opinion · 28 Apr 2022
The grouping of sequencers: The historical backdrop of sequencing DNA
Short communication · 28 Apr 2022
Cytopathology: A helpful method for diagnosing oral injuries?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pathobiology and Physiology
- SubjectBiology
- BylineArticles whose byline prints “Ms. Erika Barbarosie”

